Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase I/II study of JSKN003 in advanced malignant solid tumors in China
CTR20230072Phase 2Active
- Sponsor
- Kanion Pharmaceutical
- Start
- Mar 2023
- Modality
- Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
A Phase 2 trial of anbenitamab repodatecan in Nonhematologic neoplasms, breast cancer, gastric adenocarcinoma, gastroesophageal junction adenocarcinoma, epithelial ovarian cancer (EOC), sponsored by Kanion Pharmaceutical. Started Mar 2023; status: active.
02
Drugs
anbenitamab repodatecan
03
Conditions
Nonhematologic neoplasmsbreast cancergastric adenocarcinomagastroesophageal junction adenocarcinomaepithelial ovarian cancer (EOC)
Beyond the preview
Go deeper on CTR20230072.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20230072.